Clin Oncol | Volume 5, Issue 1 | Research Article | Open Access

Predictors of Apatinib in the Treatment of Advanced Primary Liver Cancer

Ren-Wang Chen1, Chi-Dan Wan2, Tao Zhang1, Liang-Liang Shi1, Guo-Run Fan3, Jian Chang1, Jing Zhan4, Xiao-Xiao He4, Meng-Jun Qiu4, Sheng-Li Yang1* and Jian-Li Hu1*

1Department of Cancer, Huazhong University of Science and Technology, China 2Department of Hepatobiliary Surgery, Huazhong University of Science and Technology, China 3Department of Otorhinolaryngology, Huazhong University of Science and Technology, China 4Department of Gastroenterology, Huazhong University of Science and Technology, China

*Correspondance to: Jian-Li Hu 

Fulltext PDF

Abstract

Objective: The purpose of this study is to investigate the efficacy of Apatinib in the treatment of advanced Primary Liver Cancer (PLC), analyze the factors that influence the efficacy, and find out the biomarkers that effectively predict the efficacy. Methods: Data from 87 patients with advanced PLC who received Apatinib as first-line treatment at two medical centers were retrospectively analyzed. We analyzed the clinical features and explore the prognostic factors of PLC. We correlated the clinical markers with the efficacy of Apatinib. Results: The Progression Free Survival (PFS) of the 87 patients was 8.6 ± 1.9 months (95% CI: 5.0 to 12.3). 3-month, 4-month and 5-month disease control rates were 69.0%, 59.2% and 53.5% respectively. Univariate analysis indicated that Alpha-Feto Protein (AFP), Alkaline Phosphatase (ALP), Lactate Dehydrogenase (LDH) and cirrhosis were associated with prognosis (P<0.05). Multivariate analysis indicated that ALP was negatively associated with prognosis (P<0.05). Chisquare test indicated that the serum AFP and LDH level as well as tumor diameter were statistically different between PFS ≤ 3-month and PFS>3-month groups (P<0.05). The survival analysis was conducted that the blood levels of AFP, ALP and LDH as well as with or without cirrhosis before starting Apatinib treatment can influence the survival rate of patients. Conclusion: Apatinib is an effective treatment for advanced PLC. Serum AFP, ALP and LDH level, as well as whether there is cirrhosis can be used to predict the efficacy of Apatinib

Keywords:

Apatinib; Primary liver cancer; First-line treatment; Efficacy prediction; Prognostic factors

Citation:

Chen R-W, Wan C-D, Zhang T, Shi L-L, Fan G-R, Chang J, et al. Predictors of Apatinib in the Treatment of Advanced Primary Liver Cancer. Clin Oncol. 2020; 5: 1704.

Subscribe to Our Newsletter